COVID-19 Convalescent Plasma
Sponsored by University of Chicago
The purpose of this study is to assess the feasibility of delivering anti-SARS-CoV-2 convalescent plasma to hospitalized patients with severe or life-threatening COVID-19.
Beyond supportive care, there are currently no proven treatment options for coronavirus disease (COVID-19), the infection caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Human convalescent plasma is an option for treatment of COVID-19 and could be rapidly available when there are sufficient numbers of people who have recovered and can donate high titer neutralizing immunoglobulin-containing plasma.
About COVID-19
Coronavirus disease 2019 (COVID-19) is a respiratory illness that can spread from person to person. The virus that causes COVID-19 is a novel coronavirus that was first identified during an investigation into an outbreak in Wuhan, China.
How is this study designed?
Study Type: Interventional (Clinical Trial) Estimated Enrollment: 10 participants Primary Purpose: Treatment Official Title: Pilot Study for Use of Convalescent Plasma Collected From Patients Recovered From COVID-19 Disease for Transfusion as an Empiric Treatment During the 2020 Pandemic at the University of Chicago Medical Center Actual Study Start Date: April 10, 2020 Estimated Study Completion Date: December 31, 2021
Who is this study for?
Donor Inclusion Criteria*:
- Age greater or equal to 18
- Prior diagnosis of COVID-19 documented by a laboratory test (confirmed)
- Complete resolution of symptoms at least 28 days prior to donation
Recipient Eligibility Criteria:*:
- Patients must be 18 years of age or older
- Must have laboratory-confirmed COVID-19
- Must have severe or immediately life-threatening COVID-19
- Must be less than 21 days from the start of illness
Recipient exclusion Criteria*:
- Female subjects with positive pregnancy test, breastfeeding, or planning to become pregnant/breastfeed during the study period
* Additional criteria apply. Please speak with the study team for further information.
What should I expect?
Experimental: Treatment with anti-SARS-CoV-2 convalescent plasma Infusion of one unit of anti-SARS-CoV-2 convalescent plasma ~300 mL over 4 hours
Have a question?
For general questions about COVID-19 clinical trials, please email [email protected] For study specific inquiries, submit the interest form and you'll be connected to the team.